Screener
Trevi Therapeutics, Inc. TRVI Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total other income, net | 1,700 | 1,119 |
| Loss before income taxes | (13,212) | (10,351) |
| Income tax benefit | (20) | (11) |
| Net loss | $(13,192) | $(10,340) |
| Basic and diluted net loss per common share outstanding | $(0.09) | $(0.09) |
| Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted | 145,592,901 | 117,610,750 |
| Net loss | $(13,192) | $(10,340) |
| Other comprehensive (loss) income: |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s net income?
- Trevi Therapeutics, Inc. (TRVI) reported net income of -$13.19M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s net income changed year-over-year?
- Trevi Therapeutics, Inc.'s net income decreased by 27.6% year-over-year, from -$10.34M to -$13.19M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s net income?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s net income has grown at a 5.9% compound annual growth rate (CAGR), from -$33.94M to -$42.76M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Trevi Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude